Oramed Pharmaceuticals Inc. develops proprietary technology for the oral delivery of drugs that are typically administered via injection. The company is focused on an orally ingestible insulin capsule that is in Phase 3 trials under the USFDA, aiming to transform diabetes treatment. Oramed also engages in investment activities across the biomedical landscape, leveraging its expertise to identify and capitalize on opportunities.
